Global Microbiome Market (2020 to 2030) - COVID-19 Impact and Recovery - ResearchAndMarkets.com

DUBLIN--()--The "Microbiome Global Market Report 2020-30: Covid 19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.

This report from the publisher provides the strategists, marketers and senior management with the critical information they need to assess the global microbiome market as it emerges from the COVID-19 shut down.

The global microbiome market is expected to decline from $0.34 billion in 2019 to $0.27 billion in 2020 at a compound annual growth rate (CAGR) of -20%. The decline is mainly due to the focus on COVID-19 outbreak and its treatment across the globe, resulting in patients of other illnesses delaying their episodes of care. The market is then expected to recover and reach $0.58 billion in 2023 at a CAGR of 14%.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 20+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3 working days of order.

Stringent government regulations are expected to limit the growth of the microbiome market. Regulations or restrictions by the government bodies to use human microbiome as a therapy or a diagnostic tool can be challenging for the pharmaceutical companies engaged in microbiome production. For example, in 2013, FDA released a guidance stating that fecal microbiota transplantation (FMT) procedures are not subject to FDA enforcement which became challenging for the newly emerged companies involved in microbiome development.

In January 2020, Psomagen-Macrogen Consortium acquired uBiome for a deal amount of $7.05 Million. The deal comprises of patent portfolio of 246 patents (60 registered US patents and 186 applications), nearly 300,000 sample data and laboratory equipment. Psomagen has become a key player in the microbiome sector with this acquisition.

A number of NGS (Next Generation Sequencing) programs and innovative approaches are being developed in the field of human microbiome. Sequencing of DNA present in a sample along with that of the bacteria which have been killed by the prophylactic treatment of the antibiotics is possible with the NGS technique. In 2019, Baseclear has increased its sequencing capacity by implementing Illumina NovaSeq 6000 platform which has an output of 3.0 Gb data per run.

Technological advancements such as software programs allow easy analyzing of the metagenomic datasets related to the genes of the microbiota along with user-friendliness, ease of access and with ability to provide graphical representation for easy and quick understanding of the analyzed data. Specialized software programs available for analyzing the metagenomic data are FastQC, Fastx-Toolkit, PRINSEQ, and many others. Thus, technological advancements and innovative approaches aid in growth of the human microbiome market.

The increased number of lifestyle diseases such as diabetes, cancer, depression and many others in the historical period has positively affected the microbiome market. Lifestyle changes influences the micro flora internally at every stage of life leading to lifestyle diseases and thus altering the microbiome can help in minimizing these lifestyle diseases. Worldwide from 1975 the obesity population has nearly tripled and now 30% of the population is obese. In recent studies, Fecal Microbiome Transplantation has shown beneficial results in treating patients with obesity and also diabetes. Thus, increasing lifestyle changes which lead to lifestyle diseases help drive the growth of this market.

Key Topics Covered:

1. Executive Summary

2. Microbiome Market Characteristics

3. Microbiome Market Size And Growth

3.1. Global Microbiome Historic Market, 2015 - 2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Microbiome Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

4. Microbiome Market Segmentation

4.1. Global Microbiome Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global Microbiome Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. Microbiome Market Regional And Country Analysis

5.1. Global Microbiome Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5.2. Global Microbiome Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

  • Enterome Bioscience
  • Vedanta Biosciences Inc.
  • Osel Inc.
  • Synlogic Inc.
  • Second Genome
  • Seres Therapeutics
  • Synthetic Biologics Inc.
  • uBiome, Inc.
  • Metabiomics Corporate
  • Rebiotix Inc
  • BiomX
  • Microbiome Therapeutics LLC
  • Yakult Honsha Co. Ltd
  • DuPont
  • 4D Pharma
  • BaseClear BV
  • ViThera Pharmaceuticals
  • Pharma PLC
  • Ferring Pharmaceuticals
  • Evelo Biosciences
  • LNC Therapeutics
  • E.I. du Pont de Nemours and Company
  • Clinical Microbiomics AS
  • Locus Biosciences
  • Microbiome Insights Inc.
  • MR DNA
  • PureTech Health
  • Zymo Research Corp.
  • OptiBiotix Health Plc
  • Ritter Pharmaceuticals
  • Assembly Bioscience Inc.

For more information about this report visit https://www.researchandmarkets.com/r/a49pf1

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900